Cell based therapeutics in type 1 diabetes mellitus

Fernanda Zamboni; Maurice N. Collins

doi:10.1016/j.ijpharm.2017.02.063

Cell based therapeutics in type 1 diabetes mellitus

Fernanda Zamboni, Maurice N. Collins

School of Engineering

University of Limerick

Research output: Contribution to journal › Short survey › peer-review

Abstract

This review focuses on Type 1 diabetes mellitus (T1DM) and the role of bioengineering, nanotechnology and cell therapy in its treatment. T1DM is discussed in terms of its prevalence as well as the role of the extra cellular matrix (ECM) of the pancreas in its development and mode of action. Surface engineering strategies and the chemistries behind important cell encapsulation techniques, which are emerging from recent research in immunosuppression, are described. Key enabling technologies such as therapeutic agent immobilization on cells, oxygen releasing systems, gene delivery and bio imaging are assessed with respect to T1DM. These latest cell surface technologies provide unlimited possibilities for control of cell/cell and cell/ECM interactions, allowing the ability to confer “immune camouflage”. Finally, we provide an outlook to the future of cell-based technologies for T1DM treatment and their likely deployment in clinical trials.

Original language	English
Pages (from-to)	346-356
Number of pages	11
Journal	International Journal of Pharmaceutics
Volume	521
Issue number	1-2
DOIs	https://doi.org/10.1016/j.ijpharm.2017.02.063
Publication status	Published - 15 Apr 2017

Keywords

Cells
Diabetes
Encapsulation
Gene therapy
Immunoprotection

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijpharm.2017.02.063

Cite this

@article{b182e4da33d44432bcac775e062f9097,

title = "Cell based therapeutics in type 1 diabetes mellitus",

abstract = "This review focuses on Type 1 diabetes mellitus (T1DM) and the role of bioengineering, nanotechnology and cell therapy in its treatment. T1DM is discussed in terms of its prevalence as well as the role of the extra cellular matrix (ECM) of the pancreas in its development and mode of action. Surface engineering strategies and the chemistries behind important cell encapsulation techniques, which are emerging from recent research in immunosuppression, are described. Key enabling technologies such as therapeutic agent immobilization on cells, oxygen releasing systems, gene delivery and bio imaging are assessed with respect to T1DM. These latest cell surface technologies provide unlimited possibilities for control of cell/cell and cell/ECM interactions, allowing the ability to confer “immune camouflage”. Finally, we provide an outlook to the future of cell-based technologies for T1DM treatment and their likely deployment in clinical trials.",

keywords = "Cells, Diabetes, Encapsulation, Gene therapy, Immunoprotection",

author = "Fernanda Zamboni and Collins, {Maurice N.}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier B.V.",

year = "2017",

month = apr,

day = "15",

doi = "10.1016/j.ijpharm.2017.02.063",

language = "English",

volume = "521",

pages = "346--356",

journal = "International Journal of Pharmaceutics",

issn = "0378-5173",

number = "1-2",

}

TY - JOUR

T1 - Cell based therapeutics in type 1 diabetes mellitus

AU - Zamboni, Fernanda

AU - Collins, Maurice N.

PY - 2017/4/15

Y1 - 2017/4/15

N2 - This review focuses on Type 1 diabetes mellitus (T1DM) and the role of bioengineering, nanotechnology and cell therapy in its treatment. T1DM is discussed in terms of its prevalence as well as the role of the extra cellular matrix (ECM) of the pancreas in its development and mode of action. Surface engineering strategies and the chemistries behind important cell encapsulation techniques, which are emerging from recent research in immunosuppression, are described. Key enabling technologies such as therapeutic agent immobilization on cells, oxygen releasing systems, gene delivery and bio imaging are assessed with respect to T1DM. These latest cell surface technologies provide unlimited possibilities for control of cell/cell and cell/ECM interactions, allowing the ability to confer “immune camouflage”. Finally, we provide an outlook to the future of cell-based technologies for T1DM treatment and their likely deployment in clinical trials.

AB - This review focuses on Type 1 diabetes mellitus (T1DM) and the role of bioengineering, nanotechnology and cell therapy in its treatment. T1DM is discussed in terms of its prevalence as well as the role of the extra cellular matrix (ECM) of the pancreas in its development and mode of action. Surface engineering strategies and the chemistries behind important cell encapsulation techniques, which are emerging from recent research in immunosuppression, are described. Key enabling technologies such as therapeutic agent immobilization on cells, oxygen releasing systems, gene delivery and bio imaging are assessed with respect to T1DM. These latest cell surface technologies provide unlimited possibilities for control of cell/cell and cell/ECM interactions, allowing the ability to confer “immune camouflage”. Finally, we provide an outlook to the future of cell-based technologies for T1DM treatment and their likely deployment in clinical trials.

KW - Cells

KW - Diabetes

KW - Encapsulation

KW - Gene therapy

KW - Immunoprotection

UR - http://www.scopus.com/inward/record.url?scp=85014368113&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2017.02.063

DO - 10.1016/j.ijpharm.2017.02.063

M3 - Short survey

C2 - 28242376

AN - SCOPUS:85014368113

SN - 0378-5173

VL - 521

SP - 346

EP - 356

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

IS - 1-2

ER -

Cell based therapeutics in type 1 diabetes mellitus

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this